Since 2000, Acceleris Capital have led the effort to support and capitalise early-stage technology ventures. Acceleris are lifecycle advisors and have seen success across many sectors, headlines include:

  • Approximately 70% of Acceleris Corporate clients have exited, realised value, or are still in operation

  • Across all exits, the average return is 7x

  • Acceleris have lost <10% of overall invested capital

  • 60% of our invested companies are still growing in value

Our track record is more than just financial results. We focus on our added impact to society as a whole through assisting and advising innovate smaller enterprise. Impact headlines include but aren’t limited to;

  • Bringing new sustainable agricultural technology products to field trial in 4 years

  • Supporting clinical trials of 3 new cancer drugs

  • Introducing wireless business connectivity across Europe

  • Supporting a phase 3 clinical trial of a new allergy drug